Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.79 |
| ▸ | MEN1 | O00255 | 8/20 | 0.79 |
| ▸ | MAPT | P10636 | 7/20 | 0.79 |
| ▸ | LMNA | P02545 | 6/20 | 0.79 |
| ▸ | HTT | P42858 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 5/20 | 0.71 |
| ▸ | NPC1 | O15118 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.62 |
| ▸ | RELA | Q04206 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2682054 | 0.88 | KMT2A (1.00) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL11476205 | 0.83 | KMT2A (0.81) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL10344695 | 0.83 | MEN1 (1.00) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL29077780 | 0.83 | MEN1 (0.89) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL29556162 | 0.83 | MEN1 (0.89) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL29533340 | 0.83 | MEN1 (1.00) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL16500681 | 0.82 | KMT2A (0.79) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL3076869 | 0.81 | KMT2A (0.79) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL11049956 | 0.81 | MEN1 (0.85) | KMT2AMEN1MAPTLMNAHTT | |
| SCHEMBL16488795 | 0.81 | MEN1 (0.51) | KMT2AMEN1MAPTLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381995-B1 | OIL-GELLING AGENT | UNIV SHIZUOKA NAT UNIV CORP (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-10189835-B2 | Derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2018-05-10 | — | — | US | disclosed |
| WO-2018045969-A1 | COMPOUND FOR ACTIVATING ADENOSINE MONOPHOSPHATE-ACTIVATED PROTEIN KINASE | 法玛科技顾问股份有限公司 | 2018-03-15 | — | — | WO | disclosed |
| EP-3016950-B1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663529-B2 | Tricyclic pyrido-carboxamide derivatives as rock inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-06-02 | — | — | US | disclosed |
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2008-01-17 | — | — | US | disclosed |
| US-5661153-A | FOR TREATING ALLERGIES, ASTHMA, DERMATITIS, GRAFT REJECTIONS | JAPAN ENERGY CORPORATION (JP) | 1997-08-26 | — | — | US | disclosed |
| EP-0700908-A1 | 1-Arylpyrimidine derivatives and pharmaceutical use thereof | JAPAN ENERGY CORPORATION (JP) | 1996-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189835-B2 | Derivatives and methods of treating hepatitis B infections | HAVCR2, PYGL, HCCS | KMT2A 4148/4885MEN1 4414/4885MAPT 4552/4885 |
| US-20160152627-A1 | TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | KMT2A 1131/4885MEN1 803/4885MAPT 184/4885 |
| US-20080015184-A1 | Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines | IL2, EIF2AK2, IL4 | KMT2A 2855/4885MEN1 3849/4885MAPT 2738/4885 |
| US-20180127415-A1 | DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | KMT2A 4148/4885MEN1 4414/4885MAPT 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.